New River reiterated at buy by Merrill

New River Pharmaceuticals Inc. was reiterated at a buy rating by Merrill Lynch analyst David Munno after data from an abuse liability study showed that subjects did not like NRP104 and would not use it intravenously. According to the analyst, the data indicates the lower abuse potential of NRP104, giving it better scheduling upon approval. Shares of the Radford, Va.-based pharmaceutical company were down 57 cents, or 2.07%, at $27.03 on volume of 379,083 shares versus the three-month running average of 301,269 shares. (Nasdaq: NRPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.